This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released

 

A one day meeting held on
Monday 19th September 2016
The Royal College of Physicians, London, UK


Chairs

Mark Emberton
Professor Mark Emberton
Professor of Interventional Oncology
UCL Cancer Institute
Mark LinchDr Mark Linch
Medical Oncology Consultant
University College London Hospital

From 08.00 Registration & Coffee
09.00 Welcome / setting the scene: The Chairmen
Morning Sessions: The Prostate
SESSION 1: Early Detection & Diagnostics
09.05 Introduction from session Chair: Professor Mark Emberton
09.10 MRI in prostate cancer detection
Dr Clare Allen
Consultant Radiologist, UCLH, London, UK
09.35 Understanding biomarkers when diagnosing prostate cancer
Dr Hayley Whitaker
Head of the Centre for Molecular Intervention, UCL, London, UK
10.00 Biopsies in prostate cancer
Dr Hashim Ahmed
Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK
10.25 Discussion of merits and demerits of above findings
Chairman & Speakers
10.40 Break
SESSION 2: Multidisciplinary Team Educational Session
11.10 Chair: Professor Mark Emberton
Image based personalised active surveillance
Dr Caroline Moore
Senior Clinical Researcher & Honorary Consultant Urological Surgeon, UCL & UCLH, London, UK
Tissue selective surgery
Dr Hashim Ahmed
Reader in Surgical Uro-oncology, Research Department of Urology, UCL, London, UK
Tissue selective surgery
Professor John Kelly
Professor of Uro-Oncology, UCLH, London, UK
Radiotherapy
Dr Anita Mitra
Consultant Clinical Oncologist, University College London Hospitals, London, UK
12.10 Keynote Presentation
Reflections on diagnosis and treatment: Patients’ perspectives

Professor Jan van der Meulen
Professor of Clinical Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
12.30 Lunch
Afternoon Sessions: Beyond the Prostate
SESSION 3: Metastatic Disease
13.30 Introduction from session Chair: Dr Mark Linch
13.35 Hormones
Professor Heather Payne
Consultant Clinical Oncologist, University College London Hospitals, London, UK
14.00 Chemotherapy
Dr Ursula McGovern
Consultant Medical Oncologist, University College London Hospitals, London, UK
14.25 Novel therapies
Dr Mark Linch
Consultant Medical Oncologist & Honorary Senior Lecturer, University College London Hospitals, London, UK
14.50 Discussion of merits and demerits of above findings
Chairman & Presenters
15.05 Break
15.35 Keynote Presentation
Opportunities for immunotherapies in urology

Dr Sergio Quezada
Group Leader – Immune Regulation and Tumor Immunotherapy Lab, UCL Cancer Institute, London, UK
SESSION 4: Multidisciplinary Team Educational Session
Management of Symptomatic Metastatic Prostate Cancer
16.05 Introduction from session Chair: Dr Mark Linch
Radiotherapy
Professor Heather Payne
Consultant Clinical Oncologist, University College London Hospitals, London, UK
Chemotherapy
Dr Ursula McGovern
Consultant Medical Oncologist, University College London Hospitals, London, UK
EndoUrology
Mr Daron Smith
Consultant Urological Surgeon, University College London Hospitals, London, UK
Palliative care
Professor Paddy Stone
Marie Curie Chair in Palliative and End of Life Care, University College London, UK
Uro-Oncology CNS
Janet Forgenie
Uro-Oncology Clinical Nurse Specialist, University College London Hospitals, London, UK
17.05 Summary & Close

This meeting is organised by:

New UCL Logo2 800

ATL-new-logo-July-2015-800px

 

and endorsed and supported by:

TLO
TL

The Frontiers of Oncology 2018 meetings are supported by grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.